Where To Invest Newsletter April 10, 2017

where to invest now newsletter

Where To Invest Newsletter

Where To Invest Newsletter

Read the April 10, 2017 – Where To Invest Newsletter in .pdf format — HERE


April 10, 2017

Market Strategies Newsletter

Sample Issue

 Where To Invest Newsletter


Where To Invest Newsletter


Balanced Investing Strategies To Make Money In Up Or Down Markets


A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)

Contributing Staff: Michael King, Charles Moskowitz



Proven Trading Success

Results From Our Recent Trade Alerts:


125% Profits on OIH Calls in 6 Days

130% Profits on GS Calls in 9 Days

217% Profits on XOM Calls in 9 Days

205% Profits on XOM Calls in 3 Days

105% Profits on XOM Calls in 3 Days

50% Loss on NUGT Calls in 10 Days

50% Loss on SJM Calls in 7 Days

117% Profits on GLD Calls in 3 days

50% Loss on GLD Calls in 20 days

62% Profits on XOM Calls in 20 days

50% Loss on HL Calls in 2 Days

50% Profits on PFE Calls in 2 Days

50% Loss on SPY Puts in 2 Days

50% Loss on TWTR Calls in 8 Days

31% Profits TWTR Calls in 2 Days

316% Profits on MOS Calls in 13 Days

154% Profits on MOS Calls in 11 Days

100% Profits on MOS Calls in 8 Days

50% Loss on FB Puts in 3 Days

47% Loss on K Calls in 2 Days

87% Profits on AMZN Calls in 2 Days

96% Profits on K Calls in 17 Days

16% Profits on HOG Calls in 8 Days

108% Profits on MOS Calls in 16 Days

91% Profits on MOS Calls in 15 Days


Join Today to Start Getting Profits Like These.


When you become a Trade Alerts Member:


We Do The Research and Analysis Work,

We Send You The Buy Trades,

You Make The Trades,

We Let You Know When We Are Selling and

You Take and Keep Your Gains.


To get trade alerts WHEN WE MAKE THEM, become a Member today. Go To:



To get the lowest full membership rates available now.


Where To Invest Options Trading Service

Options Trade Alerts
Charles Moskowitz Traders Discussion


The Syrian airstrike dominated the Sunday news shows and broke along partisan lines.  The question most debated was “Is this an emotional reaction or a shift away from the America first attitude of the president.”  Frankly, I have no clue, but it does show that when you sign on to a treaty against chemical warfare and violate it, there are consequences.  The other issue was “Is it legal to take action without consulting the Congress?”  This, I believe is the main point since we saw so much over-reach in the Obama presidency, that Congress feels if it doesn’t act on this it cedes the power to the White House.  We’ll see how this shakes out and only time will tell if this is really a shift in the willingness to continue to police the world.


The market internals were all over the place this week with lower volume and sentiment numbers were little changed, but the markets inability to rally back past the halfway point after the stunning reversal on Wednesday.  We will need a close over 20,800 to get me off the side of a decline of a couple more percent to work off some of the excessive gains of 7% YTD or the 15% since Election Day The only good sign is that a pullback on falling volume generally leads to a resumption of the uptrend. That, taken with the continuing fall in bullish sentiment this week should lend some support.  We are quickly reaching support in the S&P500 near 2,325 but we will need to bounce from there quickly.


I continue to favor the long side of the Silver and Gold markets and a pullback in the Oil.  I will not hesitate to abandon the SCO and AGQ trades should we continue to see weakness in either.  These are both leveraged ETFs and move rather quickly.  Since we have over 20% committed in this account I will not be issuing any new trades tonight, but will await the market’s action to make the decisions for me.


This week may see some light volume both Monday afternoon and Tuesday due to the Passover holiday…CAM



Where To Invest Options Trading Service

Options Trade Alerts Trade Table


Sold 10 OIH April 31.50 Calls
110 Gain
Bought 6 SPY April 235 Puts
Sold 4 GS April 7th 232.50 Calls
180 Gain
Sold 3 XOM April 82 Calls
261 Gain
Bought 6 SCO April 37 Calls
Bought 6 AGQ April 42 Calls
Bought 10 OIH April 31.50 Calls
Sold  3 XOM April 82 Calls ( 100% Profit Rule )
234 Gain
Bought 4 GS April  7th 232.50 Calls
Bought 6 XOM April 82 Calls
Bought 6 VRX April 12.50 Calls


3rd Week expiration when the month is listed without a date


Previous closed out trades not listed here may be seen in previous market letters in the

VIP Subscribers Members Area.


Remember, these trades are based on your participation in the

Subscriber Members Only



New Trades Will Be TEXTED To MEMBERS


For Free Where To Invest Your Money Now

High Return Investments Trade Alerts

Go To: PrincetonResearch.com/alerts.htm





Get the lowest full membership rates available.


NOTE: This is a Sample Issue Only!



Visit: PrincetonResearch.com/join.htm



Follow Our Marketed Weathered,

Time Tested Trading Rules That



Now you can profit from investing trade alerts from our traders with over 75 combined years of successful investing experience.


  • Make Money In Up Or Down Markets — Our trading alerts balanced investing strategies are designed and proven to make money in up or down markets.


  • Done For You – All the stock options picking, research and trading analysis is done for subscribers. This is not a ‘class’ or a ‘training course’… this is us doing ALL the work… from research to sending you a text on what to trade, along with recommended amounts…


  • SAFETY – We strictly follow our Tested, Market Weathered Trading Rules that are proven time and time again to protect our (and now your) investment capital from losses while effectively allowing us to Keep The Profits We Make.


So even though we trade options to get the profits you see above — We can do it with minimal risk and Maximum Profit Potential.


You Don’t Need To Learn Any Trading Skills Or

Do Any Time Consuming Analysis and Tracking


+++ We DO IT ALL FOR YOU! +++


We tell you where, when and how much to trade and you get to sit back and enjoy the rewards!


The specific buy and sell trading alerts are sent directly to you by e-mail and text message. So you can get in on and cash out on our winning trades fast and at the right time.


Get Started with Any Amount – Follow our recommended trading guidelines for a $10,000 portfolio or invest more or invest less — Whatever you are comfortable with. Your investment is protected because Time Tested Trading Rules PROTECT YOUR CAPITAL And KEEP YOUR PROFITS.


Join Us Today.

Lock in the Lowest Membership Rates Available HERE




Your Membership includes access to both:


Trade Alerts by Text Message and e-mail


The Market Investing Strategies Newsletter

Full Members Only Edition


Our Where To Invest Now For Profits In Up or Down Markets Newsletter is more compact, informative, effective and quicker to read then the major, big name publications. AND there are NO ADS to wade through.


The Members Edition Newsletter is sent to you by e-mail Monday Mornings and available in the Members Area along with our archive of past issues.



A Sample of the Where To Invest Now Newsletter

Information Our Members Get Follows



Fundamental Analysis Stocks To Buy with Stops


Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition many have been stopped out with small losses.  All indicated on the table below. Balance is critical.


We want to be long Alcoa AA at $ 32.00 which is coming into support.


Flushing Financial FFIC fell below the 50 day price moving average which was a selling opportunity. We are long FFIC at $ 19.10 and are holding long the Flushing Financial.


Bank stocks are to be bought in this reaction phase after having continued bullish into the new year.


You must use your own discretion on whether to take profits.


Boeing has gone to $ 182, above the previous high at $ 169.80-170.00, surging from a new high in defense stocks. We remain long. Boeing is on its way to $ 200.


We are disappointed with our long Bristol Myers which should have been bought at $56.20.

We originally bought BMY at $ 49.20 back on October 17th, sold on stop at 55.45 December 7th.


We re-bought Hecla HL at 5.24, which had been stopped out profitably at $ 5.64 on Dec 15th. Stay long Hecla.


Sell the ENZ. We took profits.


The HDGE is not relevant at this time.


We are looking to buy the GSCI symbol GSG, a commodity indexed fund managed by Goldman.


Symbol Name Business Description PE P/S MV mln Price Buy or Sell Limit Stop Loss

Or offset

AMZN Amazon Catalog & Mail Order 189 2.90 394B 894.88 Long Sell on stop 829x
SIMO Silicon Motion Semiconductor solutions for mobile storage and communications 9.7 2.5 1.39B  46.20 39.10


CIO City Office


Real Estate Investment Trust high quality Offices 292 5.8 396Mln  12.37 12.52


12.10x stopped out 03/09/17
GSG GSCI Commodity Indexed Fund  15.02 14.50 stopped out 3/09/17 14.50x
TPC Tutor Perini Construction 12 0.25 1.3B  32.25 19.40


28.90x new stop loss
SAVE Spirit Airlines Discount Airline 13 1.6 3.6B  51.85  48.10 51.00 stopped out 3/17/17
BMY Bristol Myers Biopharmaceutical Products 28 5.1 94.9B  53.42


Sell at 52.80x


Bought 56.20


BA Boeing Aerospace, commercial jetliners, military systems 14 0.85 81B 178.85  Long at

   132 10/04/16     

New stop loss at $ 174
HL Hecla Mining Basic Materials 44 3.61 1.7B    5.40   Long at     5.24 3/3/17

Sold at $4.84

4.85x Needs to stay above $ 5 to be long
FFIC Flushing Financial Bank Holding company Savings and loans 13 3,5 592Mln  26.12  19.10


AA Alcoa Aluminum Processing and Technology N/A 0.4 9.5B  33.73 21.15 originally bought 2/8/16 Sold at 37.89 Re-Bought at 34.40 3/10/17
ENZ Enzo Biochem Life Sciences NA 1.35 134M  8.02 Bought

 at   5.13


Sold on Opening Monday 4/3/17

Sold 8.43

BAC Bank of America Commercial Bank 10 2.02 165.3B 23.16


Bought  at 15.42


23.60x stopped out on 3/21/17
HDGE Advisor Shares Ranger Bear ETF   8.93


 Stopped out at  9.01

2/10 /17

Must close above 9.01 to be long :



$100,000 Trading Portfolio Stock Positions and Trades


Each stock is allocated a theoretical $ 5,000 share of the portfolio unless otherwise indicated.





Purchase Price Purchase Date Stop/Loss Price/Date Sold Profit/


AGQ     150   40.39       04/07
SCO      200   35.05       04/05
VRX      200   11.08       03/16
VRX      400   12.12       03/13
NUGT   300     8.92       03/13
ANW     500   10.05       02/22
GDX      150 20.99       12/05
GDX      150 20.65       12/05
RWM    100 50.60       11/21
SPXU   200 22.88       11/14
CTL       150   23.29       11/04
AMBA   100   63.75       10/13
MOS     200 27.53       05/02
EYES    500 5.04       04/04
EYES  1000 6.49       12/28
TWTR   200 28.51       10/28
MOS     100 43.55       08/14
SAN      600 8.40       12/16
TEXQY 200 6.56         7/11
REPR* 5000 0.22 10/22/12


Recommendations will be both listed in this letter and texted to members.


Previous closed out stock and option positions can be found in past Market Strategies Newsletter issues available in the VIP Subscribers Members Area.

For those of you who do not buy puts to protect your portfolio, there are many ETF’s that are the inverse of the DOW. The symbols are DOG, DXD, SDS,TZA and RWM, which go up when the  DOW, S&P 500 and Russell 2000 go down and down when they go up. The DZZ goes up double when gold goes down.



Market Strategies $100,000 Trading Account


There were three closed options positions;


20 OIH April 31.50 Calls were sold at $ 0.54

8 GS Calls were sold at $ 1.96 and the remaining

6 XOM April 82 Calls were sold at $ 1.96.


The net was again of $ 1102.


For the entire last two years on closed out trades, our hypothetical profits increased by $ 1102 to $39,224.


Open trade losses increased by $ 454 from $13,682 to $14,136.


The options expire on the third Friday of each Month unless otherwise posted.


The Stock table has the following 20 positions:


AGQ, AMBA, ANW, CTL, EYES( 2 ), GDX ( 2 ), MOS ( 2 ), NUGT, REPR, RWM, SAN, SCO,                SPXU, TEXQY, TWTR, VRX (2)    :


The options call for a $ 2,500 investment unless otherwise stated; each stock position requires $5,000 unless otherwise mentioned specifically.


Money management is based on a hypothetical $ 100,000

The 20 stock positions would cost $ 85,611

The options positions require $4,632

when combined equals $90,243

which leaves excess cash of $ 9,757


These figures are approximate and there might be errors.


We have not counted the dividends received from many previous trades such as Apple, Colgate Palmolive, JP Morgan, Mosaic, North American Tankers, STNG and Santander, their Brazil affiliate BSBR and Blue Capital Reinsurance which was sold for a profit and many others.


The trading is hypothetical and we do not count commission costs.


Executions that have occurred at or near the open or close of trading sometimes vary from our actual numbers.  For example, when something opens down and it is through our price, we take the next trade whether it is an uptick or continues lower.  This sometimes results in a 50% trade that is slightly above or below the exact number.



Previous Week’s Recommendations and

Rules for the Market Strategies

$100,000 Portfolio Trading Account


  • All options count for about $ 2,500.00 for model portfolio calculations unless

otherwise stated


  • When the option has doubled sell half the position


  • Stop Loss protection is either half or offered with each trade


  • The cost of the option is the asking price (or the price between the bid and ask,

whichever is more realistic)


  • The options will be followed until closed out.


  • Option Symbols are stock symbol with expiration month and strike price


Option           COST Date Sold Date Profit/


SPY April 235

12 lots



SCU April 37

12 lots



AGQ April 42

12 lots



OIH April 31.50

20 lots



03/31/17 0.54 04/05/2017 $ 220
GS April 7th 232.50

8 lots



03/27/17 1.96 04/05/2017 $ 360
XOM April 82

6 lots remain



03/27/17 1.52

1.61 Sold Balance




$ 468


$ 522

VRX April 12.50

12 lots





Recommendations will be both listed in this letter and texted to members.


Previous closed out stock and option positions can be found in past Market Strategies Newsletter issues available in the VIP Subscribers Members Area.



MARKET Laboratory – Weekly Changes


Prices are copied from Barron’s Weekly and Yahoo Finance and may be incorrect.



20,656.10       -7.12






S&P 500








Russell 2000








Gold (spot)




  Silver May








Heating Oil




Unleaded Gas




Natural Gas








Put/Call Ratios

S&P 100



Put/Call Ratios

CBOE Equity





151-16  +0-22

2.97% -0-03%

10 Yr. Note

124-26 +0-08  2.34% -0.04%






CRB Inflation





Barron’s* Confidence







5 Yr. Note









DJ Utilities

























M1 Money




Mar 27th



M2 Money




Mar 27th






* Component Change in the Confidence Index


M1…all money in hands of the public, Time Deposits Traveler’s Checks, Demand Deposits
M2.. adds Savings and Money Market Accounts both compared with the previous year.



Market Strategies Technical Information


                              Support/Resistance Levels:                SUPPORT                         RESISTANCE


S&P 500               2330                                     2410

Dow                   20,430                                  20,880

QQQ                   128.80                                  133.40

Transports          88.90                                     9220

NASDAQ            57.70                                            5965



This Weeks’ Economic Numbers

Earnings Releases and Media Data


Before the Open on top of the Row;

After the close below the Economics Information




10:00 hrs ISM Index March ( 57.0 vs 57.7 )

10:00 hrs Construction Spending February ( + 1.0% vs -1.0% )

14:00 hrs Auto Sales March ( NA vs 4.67 Mln Units )

14:00 hrs Truck Sales March ( NA vs 9.28 Mln Units )

 Layne Christensen LAYN ( -0.13 vs -0.84 ) SeaChange SEAC ( -0.07 vs 0.00 )

TUESDAY Bank of the Ozarks OZRK ( 0.72 vs 0.57 ) Vince Holding VNCE ( -0.05 vs 0.01 )


10:00 hrs Jolts-Job Openings February ( NA vs 5.626Mln )



Healthcare Services Group HCSG ( 0.29 vs 0.26 )

WEDNESDAY Delta Air Lines DAL ( 0.74 vs 1.32 ) Fastenal FAST ( 0.46 vs 0.44 ) Hain Celestial HAIN

( 0.55 vs 0.55 ) Jamba ( -0.07 vs -0.28 ) Shaw Communications SJR ( 0.30 vs 0.34 )


07:00 hrs MBA Mortgage Applications Index 04/08 ( NA vs -1.6% )

08:30 hrs Export Prices ex-ag March ( NA vs 0.3% )

08:30 hrs Import Prices ex-oil March ( NA vs 0.3% )

10:30 hrs Crude Inventories 04/08 ( NA vs + 1.57Mln Bbls )


DAVIDs TEA  DTEA ( 0.53 vs 0.45 ) Dominion Diamond DDC ( 0.12 vs -0.41 )

Pier 1 Imports PIR ( 0.33 vs 0.23 ) Roadrunner Transportation RRTS  0.15 vs 0.32

THURSDAY Apogee Enterprise APOG ( 0.72 vs 0.69 ) Cherokee CHKE ( 0.07 vs 0.19 ) Citigroup C

( 1.25 vs 1.10 ) Commerce Bancshares CBSH ( 0.65 vs 0.65 ) First Horizon FHN ( 0.23 vs 0.20 ) First republic Bank FRC ( 1.01 vs 0.88 ) Infosys INFY ( 15.68 vs 15.74 ) J.P. Morgan Chase JPM ( 1.52 vs 1.35 ) PacWest Bancorp PACW ( 0.72 vs 0.74 ) PNC PNC ( 1.83 vs 1.68 ) Taiwan Semi TSM ( 3.40 vs 2.50 ) Wells Fargo WFC ( 0.96 vs 0.99 )


08:30 hrs Initial Claims 4/08 ( 251K vs 234K )

08:30 hrs Continuing Claims 04/08 ( NA vs 2028 )

10:00 hrs Michigan Sentiment – Preliminary April ( 96.3 vs 96.9 )

10:30 hrs Natural Gas Inventories 04/08 ( NA vs 2 bcf )



FRIDAY Stock Markets Closed


08:30 hrs Retail Sales March ( -0.1% vs +0.1% )

Retail Sales ex-auto March ( 0.2% vs 0.2% )

08:30 hrs CPI March ( 0.0% vs +0.1% )

08:30 hrs CORE CPI March ( +0.2% vs +0.2% )

10:00 hrs Business Inventories February ( +0.3% vs +0.3% )




The U.S. Oil Rig Count increased by 10 Rigs to 672. One year ago there were 354 rigs in use. The Nat Gas Rig count increased by 5 rigs making a total of 165 and there is two rigs listed as miscellaneous totaling a US rig count of 839. Crude closed higher at $ 52.24, up $0.64 following gains the previous week of     $2.63. It is the highest level since August 28, 2015. Natural Gas closed the week up $  0.15 or +5.0% At $ 3.153..






Undervalued Small Cap Stocks


Lower Priced stocks that look to be a buy:

Repro-Med Systems, Inc. (OTCQX: REPR  0.40 )* 

CHESTER, NY / March 25, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS” or the “Company”) Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS” or the “Company”) is pleased to announce that the umbrella organization of the public health insurance in Germany approved the FREEDOM60® Infusion System for reimbursement. The FREEDOM60® System was registered January, 31st 2017 and listed in the Medical Device Registry in the category mechanical infusion pumps.  It is the ONLY device of its kind registered within Germany.


In partnership with ContraCare GmbH, a leader in Germany for Contract Management (reimbursement services) and managed Care, the RMS FREEDOM60®, FreedomEdge®, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™ are now poised to dominate this growing market in Europe.


Torsten Kühn, Chief Executive Officer of ContraCare, commented “as a premium service provider in Germany’s health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60® system with its durable and reliable syringe driver and high-quality HIgH-Flo™ subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany’s public health insurance confirms the unmet need by approving the RMS FREEDOM60® System for reimbursement.”


Eric Bauer, Chief Operating Officer of RMS commented, “It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly.  ContraCare is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line.  RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life.”

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company’s RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company’s website may be visited at www.rmsmedicalproducts.com.

ContraCare GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).


RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Pumps, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company’s RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company’s website may be visited at www.rmsmedicalproducts.com.


Enzo Biochem ( ENZ: $ 8.02 )*

Enzo Biochem closed the calendar year 2016 at $6.94 a share. For the year it was up 54.22% versus the Dow Jones +13%. The relative strength index was 53.41 which is neutral and short interest declined to 827,800 shares. However the RSI has climbed to over 80 and is now 69.08 on April 1st, 2017. Enzo’s balance sheet closed their first quarter October 31 with $67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court.


What do I look for in 2017? The market will be interesting in the first half with the Government transition to a new administration. I think the Institutional Investor will be a bit more risk adverse until the direction of the economy becomes clearer. As far as Enzo the Company is concerned they will be having their Annual Shareholders Meeting on Thursday January 5 at 9 AM at the Yale Club in New York. It will be interesting to see how Management see’s the Health Care Industry being affected by a change in the Affordable Care Act. The following week Management will be at the J P Morgan Health Care Conference in San Francisco January 9-12. I would hope to see an increase in top line revenues reflecting National rollouts of the new AmpiProbe products as well as others and more approvals of products in the pipeline. I also anticipate that we will hear the trial results from the NIH on the use of Optiquel for the treatment of Uveitis. March and April will see Summary Judgements acted on by the Court in the Delaware cases. Trial dates have already been set for Genprobe and Holgics for October, Roche in November and Becton Dickenson in December. Abbots Summary Judgement request was denied by the Court but the trial date has yet to be set. At some point the 2nd Court of Appeals will rule on Enzo’s appeal on the CT. Courts reversal of the Jury’s decision in the Enzo vs. Apalera Case. The market is giving no value, win or lose, to this decision. The stake is $65 million with no adverse effect if ruled against Enzo. Enzo should again outperform the Dow and S&P in 2017.

Updates on Delaware Litigations

The last earnings report showed a cash position in excess of $65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.

When the company gets a 500 million dollar market cap ($10.63) they will qualify for those Institutions that can’t buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.



Pressure Bio Sciences OTCQB: PBIO ( 0.32 )* Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. The primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use PBIO products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is “bottlenecked” by 30 year old methods of preparing test samples.  Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking – the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality.  It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch (“psi”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.


The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“DNA”), ribonucleic acid (“RNA”), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler®, and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction (“PULSE”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their PCT Sample Preparation System (“PCT SPS”).


The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

  • Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders – including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;
  • Pathogen inactivation (useful in vaccine development, infectious disease research, and more);
  • Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);
  • and immunodiagnostics (useful in the development and detection of biomarkers).



PBIO has secured their technology through fourteen issued United States patents and ten issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field.  They also have additional patents pending.  Research indicates that Pressure Bio Science, Inc. is the ONLY Company globally to have patents in this new science sector.



Night Food, Inc. (NGTF 0.16 )*  is a wholly-owned subsidiary of Night food Holdings incorporated in Nevada in 2013 to manufacture and distribute healthy-choice bedtime snacks. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented chocolate ingredient

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, eat right before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.

People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite. Most of the snacks that people typically eat create a disturbance in sleep, causing a person to wake up feeling unrested. Night Food offers nutrient filled alternatives to high-calorie junk foods. There are flavor filled snack bars-either Cookies and Dreams or Midnight Chocolate Crunch that will help curb hunger, satisfy cravings, improve rest and give the body essential vitamins and minerals. Consumers spend over $50 billion/ year on night-time snacks, nearly 1 billion a week.  More people desire healthy alternatives to late night consumption of the traditional fattening ice cream, chips and cookies.

Sugar and caffeine in most snacks causes disruptive sleep. Each bar has only 142 calories and 5 grams of fiber for slow absorption of energy and gives a feeling of fullness and satisfaction. There is also 132 mg of calcium and zinc for replenishing the body and feeling well rested in the morning.


Leo Motors (LEOM: $ 0. 14 )* has patents for the electric battery industry which we will be writing about in upcoming weekly reports. They have developed a lithium battery that can operate vehicles in sub-zero climates. Their subsidiary LGM has developed battery technology supported by the Korean government to make it possible to use electric battery technology for fishing boats. They have a cartridge system which is a light-weight replacement method of swapping electric batteries.


Fishing has been harmed by the noise and oil leaks from internal combustion engines. LGM has solved that problem and besides eliminating the toxic problem, operating costs are reduced by 25%.


In addition they have a special patent for averting electric hazards and shocks. Leo developed the Internet of Things for e-boats which is networked and connected with an Android Operating System. Leo’s power supply system is CAN (Controller Area Network) based, which enables mobile diagnostics between mobile devices and boats using the Leo technology.


Leo is developing a battery swap system for Kalmado in Puerto Princesa, Philippines, a world famous   tourist attraction, which is focused on green energy. They will be converting 100 boats as the environment is expected to become 100% free of the toxicity from internal combustion engines. Also, Leo has developed a battery swap system for Go-Karts to be used in malls in China, Korea and Myanmar. Leo Motors has a new carbon nanotube battery power pack that functions and supplies full power in extreme low temperatures such as below 49 degrees without the need for grid electricity.


Galaxy Gaming ( GLXZ: $ 0.62 ) is on a nice growth pattern: They are in a great business with very little aggressive competition. They have some of the best development and manufacturing of table games and related products for the casino industry worldwide. Casino operators are in search for new and challenging table games to obtain increased interest and more funds from players.


Located in over 500 casinos around the globe, the Company offers a large portfolio of the world’s most popular side bets and proprietary table games. Additionally, the Company has a line of systems and associated equipment which provide casino operators with enhanced profitability, automation and security of table game operations.



Rule 17B Attestations and Disclaimers


Princeton Research, Inc. has approximately 2,581,578 shares of AIVN both free and restricted and represents them for Investor relations. Princeton also has about 40,000 shares of TXGE. Princeton is paid $ 1,500 per month from RMS Medical Products. Princeton has bought 81,100 shares of RMS Medical Products. Princeton was paid $ 2,500 to write a report on Xinergy. Princeton has signed a contract with CBLI to be paid $ 2500 for July and August for investor relations. Princeton has been engaged by Target Energy. No contract is currently in place. Princeton was paid about 500,000 restricted shares of Leo Motors.


When there is no movement in penny stocks, even though there is none or very small losses, we will liquidate ( sold AIVN on stop ) even though we like the company, if money is needed for better opportunities.


We now believe REPR represents upside opportunity. The Target ADR trades at about $ 4.50 in U.S. vs 0.05 in Australia. Princeton owns 400,000 Australia shares and about 900 U.S. ADR’s.


Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this e-mail issue. Princeton may buy or sell its free-trading shares in companies it represents at any time.




Mike King

(702) 650-3000




Where To Invest Newsletter